Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bonesupport Holding Share Issue/Capital Change 2024

Sep 30, 2024

3016_rns_2024-09-30_13b45758-5772-4942-bd76-14e298fff277.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Press Release

30 September 2024 08:00:00 CEST

^{}[]

BONESUPPORT

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today announced a change in the number of shares and votes.

As per September 30, 2024, the total number of shares in BONESUPPORT HOLDING AB (publ) amounts to 66,710,350, divided into 65,805,195 ordinary shares with one vote per share and 905,155 series C-shares with one-tenth of a vote per share, corresponding to a total of 65,895,710.5 votes.

The change in number of shares and votes is due to the exercise of 90,000 warrants within the Company's employee stock options program. The number of ordinary shares and votes has thus increased by 18,000.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
[email protected]

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
[email protected]
www.cordcom.se

This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-09-30 08:00 CEST.

Scheelevägen 19 | Ideon Science Park | SE-223 70 Lund | Sweden


Press Release

30 September 2024 08:00:00 CEST

^{}[]

BONESUPPORT

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)

Scheelevägen 19 | Ideon Science Park | SE-223 70 Lund | Sweden